Aptus Capital Advisors LLC Has $33.58 Million Holdings in Thermo Fisher Scientific Inc. $TMO

Posted by Brian Himes on Jun 14th, 2026

Aptus Capital Advisors LLC lessened its stake in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 91.2% in the 4th quarter, HoldingsChannel reports. The fund owned 57,944 shares of the medical research company’s stock after selling 598,243 shares during the quarter. Aptus Capital Advisors LLC’s holdings in Thermo Fisher Scientific were worth $33,576,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Cordoba Advisory Partners LLC acquired a new stake in Thermo Fisher Scientific in the 4th quarter valued at about $236,000. Kestra Advisory Services LLC increased its position in Thermo Fisher Scientific by 2.4% in the 4th quarter. Kestra Advisory Services LLC now owns 27,816 shares of the medical research company’s stock valued at $16,118,000 after acquiring an additional 660 shares in the last quarter. Transamerica Financial Advisors LLC grew its position in shares of Thermo Fisher Scientific by 41.7% during the 4th quarter. Transamerica Financial Advisors LLC now owns 8,879 shares of the medical research company’s stock worth $5,145,000 after buying an additional 2,615 shares during the period. Parkside Financial Bank & Trust grew its position in shares of Thermo Fisher Scientific by 7.1% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,382 shares of the medical research company’s stock worth $801,000 after buying an additional 92 shares during the period. Finally, Marshall Wace LLP grew its position in shares of Thermo Fisher Scientific by 88.1% during the 4th quarter. Marshall Wace LLP now owns 953,828 shares of the medical research company’s stock worth $552,696,000 after buying an additional 446,665 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Down 1.4%

Shares of NYSE TMO opened at $468.80 on Friday. The stock has a market cap of $174.22 billion, a P/E ratio of 25.77, a P/E/G ratio of 2.08 and a beta of 0.88. The firm has a 50 day moving average price of $479.14 and a 200 day moving average price of $527.68. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $643.99.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last issued its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.25 by $0.19. The firm had revenue of $11.01 billion during the quarter, compared to analysts’ expectations of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The business’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Analysts expect that Thermo Fisher Scientific Inc. will post 24.85 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Monday, June 15th will be issued a dividend of $0.47 per share. The ex-dividend date is Monday, June 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. Thermo Fisher Scientific’s payout ratio is currently 10.34%.

Insider Transactions at Thermo Fisher Scientific

In related news, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the transaction, the chief operating officer owned 25,051 shares in the company, valued at approximately $11,590,095.66. The trade was a 1.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.33% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on TMO. DZ Bank began coverage on shares of Thermo Fisher Scientific in a research report on Friday, March 27th. They set a “buy” rating and a $610.00 price target for the company. Piper Sandler began coverage on shares of Thermo Fisher Scientific in a research report on Thursday. They set a “neutral” rating and a $510.00 price target for the company. Royal Bank Of Canada set a $490.00 price target on shares of Thermo Fisher Scientific and gave the stock a “sector perform” rating in a research report on Thursday, May 14th. Jefferies Financial Group upgraded shares of Thermo Fisher Scientific to a “strong-buy” rating in a research report on Friday, April 24th. Finally, Robert W. Baird lowered their price target on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and an average price target of $608.95.

Get Our Latest Stock Report on Thermo Fisher Scientific

Thermo Fisher Scientific Profile

(Free Report)

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.